Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up

Background. OT101 is a first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of transforming growth factor beta 2 (TGFβ2). Here, we report our post-hoc analysis of the single-agent activity of OT101 in adult patients with recurrent and/or refractory (R/R) high-grade gliom...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Qazi, Sanjive, Hwang, Larn, Trieu, Vuong N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966490/
https://www.ncbi.nlm.nih.gov/pubmed/31795071
http://dx.doi.org/10.3390/cancers11121892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966490/
https://www.ncbi.nlm.nih.gov/pubmed/31795071
http://dx.doi.org/10.3390/cancers11121892

Ejemplares similares